442-96-6

Basic information

• Product Name: fluoroquine
• Synonyms: fluoroquine;7-Fluoro-4-[[4-(diethylamino)-1-methylbutyl]amino]quinoline;7-Fluoro-N-[1-methyl-4-(diethylamino)butyl]quinoline-4-amine
• CAS NO: 442-96-6
• Molecular Formula: C₁₈H₂₆FN₃
• Molecular Weight: 0
• Mol File: 442-96-6.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 437.7°C at 760 mmHg
• Flash Point: 218.5°C
• Appearance: /
• Density: 1.083g/cm³
• Vapor Pressure: 7.35E-08mmHg at 25°C
• Refractive Index: 1.574
• CAS DataBase Reference: fluoroquine(CAS DataBase Reference)
• NIST Chemistry Reference: fluoroquine(442-96-6)
• EPA Substance Registry System: fluoroquine(442-96-6)

Safety Data

• Hazardous Substances Data: 442-96-6(Hazardous Substances Data)

Usage

General Description

Fluoroquinolones are a class of synthetic broad-spectrum antibiotics that contain a fluorine atom, commonly referred to as "fluoroquine." These antibiotics are used to treat a wide range of bacterial infections, including respiratory, urinary tract, and skin infections. Fluoroquinolones work by inhibiting the bacterial DNA gyrase or topoisomerase IV enzymes, which are essential for the replication and repair of bacterial DNA. However, the use of fluoroquinolones has been associated with various side effects, including tendonitis, tendon rupture, and central nervous system problems. In some cases, fluoroquinolone use has been restricted due to its potential for serious adverse effects. Despite the risks, fluoroquinolones remain a valuable tool in treating serious bacterial infections when other antibiotics are not effective.

InChI:InChI=1/C18H26FN3/c1-4-22(5-2)12-6-7-14(3)21-17-10-11-20-18-13-15(19)8-9-16(17)18/h8-11,13-14H,4-7,12H2,1-3H3,(H,20,21)

Upstream product

• 140-80-7 5-diethylamino-2-pentylamine 
• 25063-54-1 5-(((3-fluorophenyl)amino)methylidene)-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 372-19-0 meta-fluoroaniline 
• 391-83-3 7-fluoro-4-hydroxyquinoline 
• 391-82-2 4-Chloro-7-fluoroquinoline 

Relevant articles and documents

PHOSPHONATE-CHLOROQUINE CONJUGATES AND METHODS USING SAME

The present invention provides compositions and methods for providing controllable local delivery of a conjugate of chloroquine (CQ) and a bisphosphonate to treat diseases characterized by abnormal bone metabolism. In certain embodiments, the invention is used as a treatment for a subject with diseases and disorders characterized by bone loss.

Structure-activity relationships for antiplasmodial activity among 7- substituted 4-aminoquinolines

Aminoquinolines (AQs) with diaminoalkane side chains (-HNRNEt2) shorter or longer than the isopentyl side chain [-HNCHMe(CH2)3NEt2] of chloroquine are active against both chloroquine-susceptible and -resistant Plasmodium falciparum. (De, D.; et al. Am. J. Trop. Med. Hyg. 1996, 55, 579-583). In the studies reported here, we examined structure-activity relationships (SARs) among AQs with different N,N-diethyldiaminoalkane side chains and different substituents at the 7-position occupied by Cl in chloroquine. 7-Iodo- and 7- bromo-AQs with diaminoalkane side chains [-HN(CH2)2NEt2, -HN(CH2)3NEt2, or -HNCHMeCH2NEt2] were as active as the corresponding 7-chloro-AQs against both chloroquine-susceptible and -resistant P. falciparum (IC50s of 3-12 nM). In contrast, with one exception, 7-fluoro-AQs and 7-trifluoromethyl-AQs were less active against chloroquine-susceptible P. falciparum (IC50s of 15-50 nM) and substantially less active against chloroquine-resistant P. falciparum (IC50s of 18-500 nM). Furthermore, most 7-OMe-AQs were inactive against both chloroquine-susceptible (IC50s of 17-150 nM) and -resistant P. falciparum (IC50s of 90-3000 nM).